# A Study to Test Whether BI 685509 Alone or in Combination With Empagliflozin Helps People With Liver Cirrhosis Caused by Viral Hepatitis or Non-alcoholic Steatohepatitis (NASH) Who Have High Blood Pressure in the Portal Vein (Main Vessel Going to the Liver)

> **NCT05282121** · PHASE2 · TERMINATED · sponsor: **Boehringer Ingelheim** · enrollment: 90 (actual)

## Conditions studied

- Liver Diseases
- Hypertension, Portal

## Interventions

- **DRUG:** Avenciguat
- **DRUG:** Empagliflozin

## Key facts

- **NCT ID:** NCT05282121
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-06-28
- **Primary completion:** 2024-04-23
- **Final completion:** 2024-06-07
- **Target enrollment:** 90 (ACTUAL)
- **Why stopped:** Company decision
- **Last updated:** 2025-09-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05282121

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05282121, "A Study to Test Whether BI 685509 Alone or in Combination With Empagliflozin Helps People With Liver Cirrhosis Caused by Viral Hepatitis or Non-alcoholic Steatohepatitis (NASH) Who Have High Blood Pressure in the Portal Vein (Main Vessel Going to the Liver)". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT05282121. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*